-+ 0.00%
-+ 0.00%
-+ 0.00%

Vår Energi (OB:VAR) Q3 Results Fuel A Cash Flow Reset Story

Simply Wall St·10/22/2026 08:41:49
Listen to the news

Vår Energi just dropped its Q3 2026 report into a market that had already been warming up. The stock closed yesterday at NOK56.84, with a 90‑day gain of about 15%, so expectations were building. The headline is clear. High realized prices turned into strong cash generation in the quarter, with about US$1.5b in cash flow from operations after tax and roughly US$800m in free cash flow.

The mood in the share price says optimism. The numbers point to something more specific. This is a cash flow story, not an earnings hype cycle.

Love Vår Energi’s heavy cash generation but want more options with balance sheets and free cash flow working together for you? Scan through the list of solid balance sheet and fundamentals stocks (203 results).

Q3 2026 Earnings Summary

  • Revenue (Q3 2026 vs. Q3 2025): US$3,566.5m vs. US$2,115.1m (up about 69%)
  • Net Income (Excl. Extra Items, Q3 2026 vs. Q3 2025): US$303.7m vs. US$134.6m (up about 126%)
  • Basic EPS (Q3 2026 vs. Q3 2025): US$0.11 vs. US$0.053926 (up about 104%)
  • Total Oil Equivalent Production (Q3 2026 vs. Q3 2025): 34.2 MMboe vs. 34.1 MMboe (broadly stable)

Prefer clean visuals over reviewing extensive tables of numbers and dense reports on Vår Energi? See the full financial picture in an easy-to-use dashboard format, with a clear view of valuation and supporting metrics, in our company report for Vår Energi.

OB:VAR Trailing 12-Month Revenue & Expenses Breakdown as at Oct 2026
OB:VAR Trailing 12-Month Revenue & Expenses Breakdown as at Oct 2026

Evaluating Vår Energi’s Cash‑Backed Growth Story

The bullish story hangs on low cost growth projects turning into durable, cash rich output rather than just headline volume claims.

"Ramp up of major low unit cost projects such as Johan Castberg and Balder via the Jotun FPSO, with production efficiencies up to 95% and reported operating costs of around US$3 to US$5 per barrel in some assets, supports the effort to hold group production costs near US$10 per barrel and can help sustain margins and cash generation."

Q3 results give partial support. Vår Energi converted high realized prices into about US$1.5b of operating cash flow and roughly US$800m of free cash flow, even with Johan Castberg and Jotun FPSO outages and production of 369 kboepd. That points to cost discipline and asset quality helping cash generation, although group unit costs are not disclosed here to fully confirm the US$10 per barrel ambition.

The price and this Narrative do not agree. → Uncover what this Narrative says Vår Energi is actually worth.

Vår Energi: Cash Windfall, Funding Squeeze Not Resolved

The cautious view argues that Vår Energi’s growth plan relies on a tight funding equation rather than a genuinely loose balance sheet.

"Although current hedging, gas sales contracts and available liquidity of about $3.6b support the near term, the commitment to material development CapEx of roughly $2b to $2.5b per year and sustained dividend payments of $1.2b in 2025 and 2026 creates a tight balance between funding growth and distributions."

Q3 cash flow from operations of about US$1.5b and roughly US$800m of free cash flow, plus liquidity lifted to around US$7.5b, clearly ease near term pressure. However, development CapEx guidance of US$2.5b to US$2.7b and higher 2026 dividends of US$1.45b indicate that the combined growth and payout burden has not gone away, but has instead been deferred by a very strong pricing quarter.

Hunt For Quiet Cash Engines

Vår Energi just showed how a single quarter of heavy cash generation can reset a funding story. The real opportunity sits in finding stocks that could be undervalued before the market fully joins the dots.

  • Company 1 - 25% below our estimate - targets DRAM capacity and new fabs tied to AI server and infrastructure demand.
  • Company 2 - 38% below our estimate - builds an advisory platform so capital markets and private mandates replace one-deal-at-a-time dependency on M&A.
  • Company 3 - 30% below our estimate - reshapes patient care by consolidating manufacturing and clinics so higher margin prosthetics and neuro orthotics support clearer cash conversion.

Those are three of them. See every one of the 189 undervalued companies on it →